Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery

References

• Achour B, Barber J, Rostami-Hodjegan A. (2011). Cytochrome p450 pig liver pie: determination of individual cytochrome p450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectroscopy. Drug Metab Dispos 39:2130–2134.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–420.
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Soucek P, Anzenbacherová E, Gut I, Hrubý K, Svoboda Z, Kvetina J. (1998). Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab Dispos 26:56–59.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Broccatelli F, Oprea TI. (2011). BDDCS applied to over 900 drugs. AAPS J 13:519–547.
   PubMed Web of Science ®Google Scholar
• Bernard O, Guillemette C. (2004). The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775–778.
   PubMed Web of Science ®Google Scholar
• Bowalgaha K, Miners JO. (2001). The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605–609.
   PubMed Web of Science ®Google Scholar
• Cassidy MK, Houston JB. (1980). In vivo assessment of extrahepatic conjugative metabolism in first pass effects using the model compound phenol. J Pharm Pharmacol 32:57–59.
   PubMed Web of Science ®Google Scholar
• Cassidy MK, Houston JB. (1984). In vivo capacity of hepatic and extrahepatic enzymes to conjugate phenol. Drug Metab Dispos 12:619–624.
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. (2009). Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073–1083.
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864–873.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, Obach RS. (2008). Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21:2260–2271.
   PubMed Web of Science ®Google Scholar
• Desille M, Corcos L, L’Helgoualc’h A, Frémond B, Campion JP, Guillouzo A, Clément B. (1999). Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. Transplantation 68:1437–1443.
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Lin H, Hu M. (2004). Disposition mechanisms of raloxifene in the human intestinal Caco-2 model. J Pharmacol Exp Ther 310:376–385.
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu Y, Lin H, Hu M. (2005). Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785–794.
   PubMed Web of Science ®Google Scholar
• Kararli TT. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351–380.
   PubMed Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700.
   PubMed Web of Science ®Google Scholar
• Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, Kume T. (2011). Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos 39:1495–1502.
   PubMed Web of Science ®Google Scholar
• Lundahl A, Hedeland M, Bondesson U, Lennernäs H. (2011). In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5a-reductase inhibitor finasteride and the effects of coadministered ketoconazole. Drug Metab Dispos 39:847–857.
   PubMed Web of Science ®Google Scholar
• Miners JO, Knights KM, Houston JB, Mackenzie PI. (2006). In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531–1539.
   PubMed Web of Science ®Google Scholar
• Mistry M, Houston JB. (1985). Quantitation of extrahepatic metabolism. Pulmonary and intestinal conjugation of naphthol. Drug Metab Dispos 13:740–745.
   PubMed Web of Science ®Google Scholar
• Mistry M, Houston JB. (1987). Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 15:710–717.
   PubMed Web of Science ®Google Scholar
• Mizuma T. (2009). Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140–141.
   PubMed Web of Science ®Google Scholar
• Myers MJ, Farrell DE, Howard KD, Kawalek JC. (2001). Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metab Dispos 29:908–915.
   PubMed Web of Science ®Google Scholar
• Nordgren A, Karlsson T, Wiklund L. (2002). Glutamine concentration and tissue exchange with intravenously administered alpha-ketoglutaric acid and ammonium: a dose-response study in the pig. Nutrition 18:496–504.
   PubMedGoogle Scholar
• Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, Lennernäs H. (2006). First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182–1189.
   PubMed Web of Science ®Google Scholar
• Raoof AA, van Obbergh LJ, de Ville de Goyet J, Verbeeck RK. (1996). Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney. Eur J Clin Pharmacol 50:91–96.
   PubMed Web of Science ®Google Scholar
• Soucek P, Zuber R, Anzenbacherová E, Anzenbacher P, Guengerich FP. (2001). Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 1:11.
   PubMedGoogle Scholar
• Szotáková B, Baliharová V, Lamka J, Nozinová E, Wsól V, Velík J, Machala M, Neca J, Soucek P, Susová S, Skálová L. (2004). Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res Vet Sci 76:43–51.
   PubMed Web of Science ®Google Scholar
• Thörn HA, Hedeland M, Bondesson U, Knutson L, Yasin M, Dickinson P, Lennernäs H. (2009). Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. Drug Metab Dispos 37:2186–2196.
   PubMedGoogle Scholar
• Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernäs H. (2011). Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 43:89–98.
   PubMed Web of Science ®Google Scholar
• Trdan T, Roškar R, Trontelj J, Ravnikar M, Mrhar A. (2011). Determination of raloxifene and its glucuronides in human urine by liquid chromatography-tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 879:2323–2331.
   PubMed Web of Science ®Google Scholar
• Trontelj J, Bogataj M, Marc J, Mrhar A. (2007). Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 855:220–227.
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. (2001). Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405–414.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Nakajima M, Yokoi T. (2002). Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462–1469.
   PubMed Web of Science ®Google Scholar
• Veroli P, O’Kelly B, Bertrand F, Trouvin JH, Farinotti R, Ecoffey C. (1992). Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth 68:183–186.
   PubMed Web of Science ®Google Scholar